SPONSORED RESEARCH: Leveraging quality improvement and implementation science to improve guideline concordant care in metastatic prostate cancer
February 10, 2026
Pictured Above: Callie Walsh-Bailey, PhD
Read a Q&A Below:
Callie Walsh-Bailey, PhD, MPH and the team at Northwestern University’s Feinberg School of Medicine Department of Medical Social Sciences (MSS) received a grant from Pfizer titled, “Leveraging quality improvement and implementation science to improve guideline concordant care in metastatic prostate cancer.” Co-investigators include: Rinad Beidas, PhD, Jennifer Young, PhD, Laura Rasmussen-Torvik, PhD, Lisa Castillo, MS, Maha Hussain, MD, and Hiten Patel, MD.
What are the aims of the project?
The overall goal of this project is to improve guideline-concordant genetic and genomic testing and the delivery of evidence-based biomarker-directed treatments for metastatic prostate cancer in community oncology settings. This project has two aims. The first it to engage community oncology clinicians in a virtual learning collaborative to a) increase knowledge about guideline-concordant biomarker testing in metastatic prostate cancer and b) build skills in quality improvement and implementation science to lead practice change efforts. The second aim is to conduct a multi-modal education campaign to disseminate learnings and best practice in guideline-concordant care in metastatic prostate cancer.
What are your next steps?
Our project officially launches at the end of January. Over the next few months, we will focus on curriculum development and solicitation of applications for clinicians to participate in the virtual learning collaborative, which we expect to launch this summer.
What do you hope will come out of this funded research?
Our hope is to leverage quality improvement, implementation science, and best practices from adult learning to build capacity among community oncology clinicians to lead practice change efforts to address a critical gap in care for patients diagnosed with metastatic prostate cancer. We also hope to identify key learnings across sites represented in the learning collaborative that can be translated to other settings to improve care delivery in community oncology settings.